These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24750480)

  • 1. Anaphylaxis following the intravenous administration of continuous erythropoietin receptor activator in a haemodialysis patient.
    Oh DJ
    Nephrology (Carlton); 2014 May; 19(5):304. PubMed ID: 24750480
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anaphylaxis due to drugs].
    Suzuki I
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():313-7. PubMed ID: 18074554
    [No Abstract]   [Full Text] [Related]  

  • 3. Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa.
    Pannier A; Jordan P; Dougherty FC; Bour F; Reigner B
    Curr Med Res Opin; 2007 Dec; 23(12):3025-32. PubMed ID: 17961301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.
    Kessler M; Martínez-Castelao A; Siamopoulos KC; Villa G; Spinowitz B; Dougherty FC; Beyer U
    Hemodial Int; 2010 Apr; 14(2):233-9. PubMed ID: 19888948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine.
    Sellaturay P; Nasser S; Islam S; Gurugama P; Ewan PW
    Clin Exp Allergy; 2021 Jun; 51(6):861-863. PubMed ID: 33825239
    [No Abstract]   [Full Text] [Related]  

  • 6. Resolution of epoetin-induced pure red cell aplasia 2 years later, successful re-challenge with continuous erythropoiesis receptor stimulator.
    Lim SK; Bee PC; Keng TC; Chong YB
    Clin Nephrol; 2013 Sep; 80(3):227-30. PubMed ID: 23298519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrogol hypersensitivity in multiple drug allergy.
    Bommarito L; Mietta S; Nebiolo F; Geuna M; Rolla G
    Ann Allergy Asthma Immunol; 2011 Dec; 107(6):542-3. PubMed ID: 22123387
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of anaphylaxis caused by macrogol 3350 after injection of a corticosteroid.
    Borderé A; Stockman A; Boone B; Franki AS; Coppens MJ; Lapeere H; Lambert J
    Contact Dermatitis; 2012 Dec; 67(6):376-8. PubMed ID: 23151193
    [No Abstract]   [Full Text] [Related]  

  • 9. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.
    Hirai T; Nishizawa Y; Nakazono H; Asai M; Yamashita H; Sasaki A; Yamashita T; Yamashita K; Shigemoto K; Harada S; Mizuiri S
    Ther Apher Dial; 2013 Oct; 17(5):498-503. PubMed ID: 24107278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from i.v. to s.c. epoetin in hemodialysis patients.
    Knauss MD; Walton T; Macon EJ
    Am J Health Syst Pharm; 2002 Sep; 59(18):1783-4. PubMed ID: 12298119
    [No Abstract]   [Full Text] [Related]  

  • 11. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgE-mediated anaphylaxis to antacid.
    Lauerma AI; Petman L; Mäkinen-Kiljunen S
    Allergy; 2001 Jun; 56(6):580. PubMed ID: 11421910
    [No Abstract]   [Full Text] [Related]  

  • 13. Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study.
    Dellanna F; Winkler RE; Bozkurt F; Schettler V; Graf S; Bockreiss N; Fliser D;
    Int J Clin Pract; 2011 Jan; 65(1):64-72. PubMed ID: 21091595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Life-threatening, multiple hypersensitivity reactions induced by rifampicin in one patient with pulmonary tuberculosis.
    Luzzati R; Giacomazzi D; Franchi F; Barcobello M; Vento S
    South Med J; 2007 Aug; 100(8):854-6. PubMed ID: 17715477
    [No Abstract]   [Full Text] [Related]  

  • 15. [Parenteral iron therapy: problems and possible solutions].
    Hoigné R; Breymann C; Künzi UP; Brunner F
    Schweiz Med Wochenschr; 1998 Apr; 128(14):528-35. PubMed ID: 9592894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study.
    Sánchez-Fructuoso AI; Ruiz JC; Torregrosa JV; González E; Gómez E; Gallego RJ; Troya MI; Jimenez C; Llamas F; Romero R; Bernis C; Crespo JF; Guirado L;
    Adv Ther; 2012 Nov; 29(11):979-91. PubMed ID: 23160946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta.
    Gertz B; Kohler E; Kes P; Essaian A; Bias P; Buchner A; Elsässer R
    Curr Med Res Opin; 2010 Oct; 26(10):2393-402. PubMed ID: 20812790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaphylactic shock after oral intake and contact urticaria due to polyethylene glycols.
    Co-Minh HB; Demoly P; Guillot B; Raison-Peyron N
    Allergy; 2007 Jan; 62(1):92-3. PubMed ID: 17156356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous erythropoietin receptor activator (Mircera) for renal anemia.
    McGahan L
    Issues Emerg Health Technol; 2008 Feb; (113):1-6. PubMed ID: 18354858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug allergy].
    Samoĭlova LN; Popova NG; Tabakova TV
    Med Sestra; 1989 Oct; 48(10):41-4. PubMed ID: 2615622
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.